Mostrando 10 resultados de: 11
Filtros aplicados
Subtipo de publicación
Article(11)
Publisher
American Heart Journal(2)
New England Journal of Medicine(2)
The Lancet(2)
Canadian Journal of Cardiology(1)
Circulation(1)
Área temáticas
Enfermedades(11)
Farmacología y terapéutica(7)
Medicina y salud(5)
Cirugía y especialidades médicas afines(2)
Problemas sociales y servicios a grupos(2)
Área de conocimiento
Medicina interna(6)
Cardiovascular efficacy and safety of bococizumab in high-risk patients
ArticleAbstract: BACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilPalabras claves:Autores:Abbott J.D., Amarenco P., Anderson P., Baultrukonis D., Black H., Blake G., Borer J.S., Brunell R., Buonanno M., Carmena R., Chakrabarti A., Chaudhuri S., Chun H., Civeira F., Colquhoun D., Conde D., Cortada J.B., Curto M., Dan G.A., Dearborn-Tomazos J., Edes I., Epsley C., Evans B., Flather M., Foody J., Frederich R., Frolova M., Furie K.L., Gao R., Gelfand E., Glynn R.J., Goetsch M., Grégoire J., Grobbee D., Hessinger D., Hwang J.J., Jacoby D., Jadbabaie F., Jensen H.K., Johnson M., Jukema J.W., Kahan T., Karpov Y., Kastelein J.J.P., Koenig W., Lee C.W., Leiva Pons J.L., Lorenzatti A.J., Lotan C., Maggioni A.P., Manga P., Masiukiewicz U., McCullough L., McMurray J.J.V., McNamara R., McPherson C., Mellbin L., Miller M., Missault L., Montalescot G., Mosterd A., Mridha K., Murin J., Neaton J., Nicolau J.C., Nissen S.E., Noble S., O’Neill B., Piazza G., Pinto D., Ponikowski P., Powell C., Pride Y., Revkin J., Ridker P.M., Sandra Verónica Falconí Peláez, Sansing L.H., Santos R.D., Savolainen M., Savonitto S., Schiele F.N., Schindler J., Schwartz P.F., Shear C.L., Silverman I.E., Solar M., Soran H., Sritara P., Tarasenko L., Tardif J.C., Tökgozoğlu L., Urina M., Vrablik M., Wang E., Wei C., Welty F., White H.D., Wright R.S., Yunis C., Zannad F.Fuentes:googlescopusMortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease
ArticleAbstract: Background: The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily comparedPalabras claves:aspirin, Coronary artery disease, Mortality , Peripheral artery disease, rivaroxabanAutores:Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Connolly S.J., Dagenais G.R., Eikelboom J.W., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Maggioni A.P., Muehlhofer E., Sharma M., Shestakovska O., Yusuf S.Fuentes:googlescopusHealth-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries
ArticleAbstract: BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there arPalabras claves:health status, Heart Failure, Left, prognosis, quality of life, Ventricular functionAutores:Alhabib K.F., Balasubramanian K., Bayes-Genis A., Budaj A.J., Dans A.M., Dokainish H., Dzudie A., Ezekowitz J.A., Fox K.A.A., Fukakusa B., Grinvalds A., Johansson I., Joseph P.G., Kamath D., Karaye K.M., Lanas F.T., Lund L.H., Maggioni A.P., Makubi A., McCready T., McMurray J.J.V., PATRICIO LOPEZ -JARAMILLO, Probstfield J.L., Silva-Cardoso J., Sliwa K., Temizhan A., Teo K.K., Wittlinger T., Yusuf S.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
ArticleAbstract: Aims Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insPalabras claves:Autores:Accatoli A., AHUAD GUERRERO R.A., Alvarez C., Alvarisqueta A., Amuchastegui M., Angos M., Ankudowikz V., Arias P., Baglivo H., Bagur R., Baigorria A., Baselga P., Bello F., Bertrand B., Birkeland K.I., Bono J., Bosch J.J., Brito S., Budaj A.J., Bustamante Labarta M., Bustos B., Buzeki R., Cabut A.M., CACCAVO A., Cantalupi H., Canteros M.C., Capozzi M.N., Cardona E., Cardone M., CARTASEGNA L.U.I.S., Cassetari A., Castano P., Castellanos R., Cerdan M.A., Chazova I.E., Cismondi M.T., Commerford P.J., Contreras A., Coria G., Corinaldesi F., Costa G., Costa Vitali A., Crespo C., Cruz M., Cuello J.L., Cuneo C.A., Dagenais G.R., Danilova L., Davies M., De Loredo L., De Maria M., Denaro R., Devoto C., Díaz R., Faingold C., Falu R., Fernando R., Fodor G.J., Gamiz J., Gerstein H.C., Gilbert R., Gomis R., Hâncu N., Hanefeld M., Hildebrandt P., Johnston P., Kacerovsky-Bielesz G., Keltai M., Kim J., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., Maggioni A.P., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mendoza I., Morillo C.A., Pan C., PATRICIO LOPEZ -JARAMILLO, Pirags V., Probstfield J.L., Profozic V., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rouleau J.L., Rydén L.E., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Vige R., Yale J.F., Yusuf S.Fuentes:scopusRationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
ArticleAbstract: Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patientsPalabras claves:Autores:Aguilar D., Aizenberg D., Allen P., Alvarez C., Alvarisqueta A., Amerena J., Baccaro C., Barkoudah E., BARTOLACCI I.P., Bentley-Lewis R., BORDONAVA A.P., Brahimi A., Bustamante Labarta M., CACCAVO A., Calella P., Cantero M., Charytan D., Chaturvedi N., Claggett B., Codutti R., Commendatore V., Costamagna O., Cuello J.L., Danilova L., Del Prato S., DeMets D., DIaz R., Dickstein K., Fasching P., Fernandez A., Finn P., Flynn A., GARCIA DURAN R.O., Gerstein H.C., Gomez Vilamajo O., Gorban De Lapertosa S., Granger C.B., GRINFELD D., Hartley L.H., Henderson G., Hermida S., Johnston P., Joseph J., Kaplan A., Køber L.V., Lagrutta M., Lawson F., Leon De La Fuente R., Lewis E.F., Licheri A., Lieberman P., LUCIARDI H.L., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Marino J., McMurray J.J.V., Montaña O., Novaretto L., O'Reilly E., Odutayo K., Orio S., Orlandini A., Oviedo A., Patel K., Patocchi C., Paul V., Pérez Manghi F., Petrie J., Pfeffer M.A., Pieber T., Ping L., Probstfield J.L., Raccah D., Rajesh V., Ramos H., Riddle M.C., Rolandi F., Rouleau J.L., Saa Zarandon R., Saavedra S.S., Sangla K., Scarpa A., Schattner M., SCHIAVI L.B., SCHYGIEL P.O., Solomon S.D., Tardif J.C., Trivi M., Ulla M., Urdiales P., Vallejos J., Van Gaal W., Vazir A., VICO M., Waisman F., Weinrauch L., Wu Y., Yan C. Duarte-Vera, Yeap B., Zuraw B.L.Fuentes:scopusRationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial
ArticleAbstract: Background: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensitiePalabras claves:Anticoagulant, Clinical trial, COGNITION, magnetic resonance imaging, prevention, silent infarctAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Cook-Bruns N., Dagenais G.R., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Ha J.W., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Wong G., Yuan F., Yusuf S., Zhu J.Fuentes:googlescopusRivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is aPalabras claves:Autores:ABIB E., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., ALVAREZ M., Anand S.S., Avezum A.J., Barbieri M., BARTOLACCI I.P., Berkowitz S.D., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Connolly S.J., Cook-Bruns N., COSTABEL J.P., CUADRADO J., Cuneo C.A., Dagenais G.R., Dans A.M., DEBONNAIRE P., DRAN R.D., DUJARDIN K.A.R.L., Dyal L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., Felix Camilo, FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., Guzik T.J., GUZMAN L.U.I.S., Ha J.W., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., Hori M., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Keltai K., Lanas F., LEROY J.E.A.N., LITVAK BRUNO M.R., Liu L., Lonn E.M., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Metsarinne K.P., Montaña O., NANI S., Novaretto L., O’Donnell M., Parkhomenko A.N., PELAGAGGE M.J., Precoma D.B., RECH R., Reis G., ROSSI DOS SANTOS F., ROSSI P., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Torp-Pedersen C., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yusoff K., Yusuf S., ZAIDMAN C., ZIMMERMANN S.L.Fuentes:googlescopusRivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Patients with peripheral artery disease have an increased risk of cardiovascular morbidiPalabras claves:Autores:Aboyans V., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., Alings M., ALVAREZ M., Anand S.S., Avezum A.J., Bangdiwala S.I., Barbieri M., BARTOLACCI I.P., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Chen E., Commerford P.J., Connolly S.J., COSTABEL J.P., CUADRADO J., Cuneo C.A., DEBONNAIRE P., DIaz R., DRAN R.D., DUJARDIN K.A.R.L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., GUZMAN L.U.I.S., Hart R.G., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Kakkar A.K., Keltai K., Leong D.P., LEROY J.E.A.N., Lewis B.S., LITVAK BRUNO M.R., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Misselwitz F., Montaña O., NANI S., Novaretto L., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, PELAGAGGE M.J., Pogosova N., Precoma D.B., Reis G., ROSSI DOS SANTOS F., ROSSI P., Rydén L.E., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Störk S., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Vanassche T., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., Vinereanu D., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yan Duarte, Yusuf S., ZAIDMAN C., Zhu J., ZIMMERMANN S.L.Fuentes:scopus